Phosphodiesterase type 5 inhibition in cardiovascular disease: Experimental models and potential clinical applications

European Heart Journal, Supplement

Volumn 4, Issue H, 2002, Pages

  Jackson, Graham ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Coronary heart disease; Heart failure; Pulmonary hypertension; Sildenafil citrate

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NUCLEOTIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SILDENAFIL; UNCLASSIFIED DRUG;

BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CORPUS CAVERNOSUM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; EXERCISE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PENILE BLOOD VESSEL; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; VASODILATATION;

EID: 0036891834     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90048-9     Document Type: Review

References (25)

1. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-4.
2. Stasch JP, Becker EM, Alonso-Alija C et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-5.
3. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000; 184: 409-20.
4. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2000; 12 (suppl 4): S34-8.
5. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C-12C.
6. Rybalkin SD, Bornfeldt KE, Sonnenburg WK et al. Calmodulinstimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 1997; 100: 2611-21.
7. Katz SD, Balidemaj K, Homma S et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-51.
8. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
9. Zhao L, Mason NA, Morrell NW et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-8.
10. Lepore JJ, Pereira N, Maroo A et al. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension [abstract 1247]. Circulation 1999; 100(18 suppl 1): 1-240.
11. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307-10.
12. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.
13. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-22.
14. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342.
15. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: Short and long-term symptomatic benefit. Int J Clin Pract 2002; 56: 397-8.
16. Jackson G. Phosphodiesterase 5 inhibition: Effects on the coronary vasculature. Int J Clin Pract 2001; 55: 183-8.
17. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-6.
18. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
19. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial. JAMA 2002; 287: 719-25.
20. Rosano GMC, Leonardo F, Pagnotta P et al. Effects of phosphodiesterase-inhibition on myocardial ischemia in patients with chronic stable angina in therapy with β-blockers [abstract]. Eur Heart J 1999; 20: 541.
21. Fox KM, Thadani U, Ma PTS, Nash SD, Keltai M. Time to limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: Effect of sildenafil citrate [abstract 2846]. Circulation 2001; 104(17 suppl II): II-601-2.
22. Jackson G, Keltai M, Gillies H, Czorniak M, Keating Z. Viagra is well tolerated by subjects with stable angina and erectile dysfunction during incremental treadmill exercise [abstract 596]. Presented at the XVIIth Congress of the European Association of Urology; February 23-26 2002: Birmingham, U.K.
23. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-8C.
24. Cheitlin MD, Hutter AM Jr, Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999; 99: 168-77.
25. Sildenafil Citrate (Viagra®) Prescribing Information. New York: Pfizer; 1999.